The pivotal trials establishing PD-1 inhibitors as standard therapy included patients with known METex14 skipping mutations and those without next-generation sequencing (NGS) who were presumed to have wild-type tumors.11, 12, 13, 14, 15 Given the low prevalence of METex14 skipping mutations in NSCLC, treatment responses have not been separately analyzed in clinical studies. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.